ReviewSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2011
Animal models of the cancer anorexia-cachexia syndrome.
Review in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 89 citations in OpenAlex.
- Chemotherapy-induced cachexia dysregulates hypothalamic and systemic lipoamines and is attenuated by cannabigerol.Journal of cachexia, sarcopenia and muscle · 2019Trial
- Dependence of energy balance and hypothalamic neuropeptide gene expression on initial tumor load in mice.Frontiers in oncology · 2026Article
- Gut microbiota in cancer cachexia: a new frontier for research and therapy.Genes & nutrition · 2025Review
- Early adipose tissue wasting in a preclinical model of human lung cancer cachexia.Cell reports · 2025Article
- Reduced Muscle Loss in Patients With NSCLC Taking Fibrates: Findings From a Retrospective Observational Study.Journal of cachexia, sarcopenia and muscle · 2025Observational
- Modulating the Gut-Muscle Axis: Increasing SCFA-Producing Gut Microbiota Commensals and Decreasing Endotoxin Production to Mitigate Cancer Cachexia.Microorganisms · 2025Review
- Cell-death induced immune response and coagulopathy promote cachexia inbioRxiv : the preprint server for biology · 2025Article
- Cancer cachexia: multilevel metabolic dysfunction.Nature metabolism · 2024Review
- Metabolic, Inflammatory, and Molecular Impact of Cancer Cachexia on the Liver.International journal of molecular sciences · 2024Review
- A comprehensive review of animal models for cancer cachexia: Implications for translational research.Genes & diseases · 2024Review
- AMPK as a mediator of tissue preservation: time for a shift in dogma?Nature reviews. Endocrinology · 2024Review
- OBSERVE: guidelines for the refinement of rodent cancer models.Nature protocols · 2024Review
- Defining and Addressing Research Priorities in Cancer Cachexia through Transdisciplinary Collaboration.Cancers · 2024Review
- Platelet status in cancer cachexia progression in ApcFrontiers in immunology · 2023Article
- Leucine Supplementation in Cancer Cachexia: Mechanisms and a Review of the Pre-Clinical Literature.Nutrients · 2022Review
- Cannabinoids orchestrate cross-talk between cancer cells and endothelial cells in colorectal cancer.Cancer gene therapy · 2022Article
- Mycobiota and C-Type Lectin Receptors in Cancers: Know thy Neighbors.Frontiers in microbiology · 2022Review
- Physiologic and molecular characterization of a novel murine model of metastatic head and neck cancer cachexia.Journal of cachexia, sarcopenia and muscle · 2021Article
- Article
- Fungal Dysbiosis Correlates with the Development of Tumor-Induced Cachexia in Mice.Journal of fungi (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsCancer cachexia, a complex wasting syndrome, is common in palliative medicine. Animal models expand our understanding of its mechanisms. A review of cancer cachexia and anorexia animal models will help investigators make an informed choice of the study model. RESULTS AND DISCUSSION: Cancer-anorexia cachexia animal models are numerous. No one is ideal. The choice should depend on the research question. To investigate cancer-anorexia cachexia independent of pro-inflammatory cytokine effects, the MAC16 ADK and XK1 are useful. MAC16 ADK helps study the host's tumor metabolic effects, independent of any anorexia or inflammation. XK1 is both anorectic and cachectic, but data about it is limited. All other models induce a host inflammatory response. The Walker 256 ADK and MCG 101 are best avoided due to excessive tumor growth. Since individual models do not address all aspects of the syndrome, use of a combination seems wise. Suggested combinations: MAC16-ADK (non-inflammatory and non-anorectic) with YAH-130 (inflammatory, anorectic, and cachectic), Lewis lung carcinoma (slow onset anorexia) or prostate adenocarcinoma (inflammatory, anorectic but not cachectic) with YAH-130.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.